These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8533580)

  • 21. A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines.
    Steinhoff MC; Reed GF; Decker MD; Edwards KM; Englund JA; Pichichero ME; Rennels MB; Anderson EL; Deloria MA; Meade BD
    Pediatrics; 1995 Sep; 96(3 Pt 2):567-70. PubMed ID: 7659477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reactogenicity and immunogenicity of a three-component acellular pertussis vaccine administered as the primary series to 2, 4 and 6 month old infants in the United States.
    Bernstein HH; Rothstein EP; Pichichero ME; Green JL; Reisinger KS; Blatter MM; Halpern J; Arbeter AM; Bernstein DI; Smith V
    Vaccine; 1995 Dec; 13(17):1631-5. PubMed ID: 8719512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a new highly purified pertussis vaccine in infants and children.
    Edwards KM; Bradley RB; Decker MD; Palmer PS; Van Savage J; Taylor JC; Dupont WD; Hager CC; Wright PF
    J Infect Dis; 1989 Nov; 160(5):832-7. PubMed ID: 2809258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
    Tozzi AE; Anemona A; Stefanelli P; Salmaso S; Ciofi degli Atti ML; Mastrantonio P; Giammanco A;
    Pediatrics; 2001 Feb; 107(2):E25. PubMed ID: 11158499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of gender, race, and parental education on immunogenicity and reported reactogenicity of acellular and whole-cell pertussis vaccines.
    Christy C; Pichichero ME; Reed GF; Decker MD; Anderson EL; Rennels MB; Englund JA; Edwards KM; Steinhoff MC
    Pediatrics; 1995 Sep; 96(3 Pt 2):584-7. PubMed ID: 7659481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody response and reactions to completion of a four-dose series with a two- or three-component acellular pertussis vaccine compared to whole cell pertussis vaccine.
    Pichichero ME; Green JL; Francis AB; Marsocci SM; Murphy AM; Buscarino C
    Scand J Infect Dis; 1996; 28(2):159-63. PubMed ID: 8792483
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and children.
    Podda A; Carapella De Luca E; Titone L; Casadei AM; Cascio A; Bartalini M; Volpini G; Peppoloni S; Marsili I; Nencioni L
    J Pediatr; 1993 Jul; 123(1):81-4. PubMed ID: 8320630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
    Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
    Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum IgG antibody responses to pertussis toxin and filamentous hemagglutinin in nonvaccinated and vaccinated children and adults with pertussis.
    Trollfors B; Taranger J; Lagergård T; Sundh V; Bryla DA; Schneerson R; Robbins JB
    Clin Infect Dis; 1999 Mar; 28(3):552-9. PubMed ID: 10194077
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Japanese clinical trials with Takeda acellular pertussis vaccine.
    Kuno-Sakai H; Kimura M; Ozaki K; Isomura S; Kamiya H; Nii R; Kato T; Horiuchi K; Syukuda Y; Fujita I
    Tokai J Exp Clin Med; 1988; 13 Suppl():15-9. PubMed ID: 2908519
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance.
    Miller E; Ashworth LA; Redhead K; Thornton C; Waight PA; Coleman T
    Vaccine; 1997 Jan; 15(1):51-60. PubMed ID: 9041666
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative study of a whole-cell pertussis vaccine and a recombinant acellular pertussis vaccine. The Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; De Luca EC; Contu B; Furlan R; Maida A; Moiraghi A; Stramare D; Titone L; Uxa F; Di Pisa F; Peppoloni S
    J Pediatr; 1994 Jun; 124(6):921-6. PubMed ID: 8201477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study.
    Englund JA; Decker MD; Edwards KM; Pichichero ME; Steinhoff MC; Anderson EL
    Pediatrics; 1994 Jan; 93(1):37-43. PubMed ID: 8265321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does whole-cell pertussis vaccine protect black South African infants? Assessment of post-vaccination events and antibody responses to pertussis toxin, filamentous haemagglutinin and agglutinogens 2 and 3.
    Ramkissoon A; Coovadia HM; Loening WE; Ndlovana M
    S Afr Med J; 1991 Jun; 79(11):645-9. PubMed ID: 1675492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of whole-cell pertussis vaccine vs an acellular vaccine containing agglutinogens.
    Miller E; Ashworth LA; Robinson A; Waight PA; Irons LI
    Lancet; 1991 Jan; 337(8733):70-3. PubMed ID: 1670725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
    Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
    Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mucosal and systemic antibody responses against an acellular pertussis vaccine in mice after intranasal co-administration with recombinant cholera toxin B subunit as an adjuvant.
    Isaka M; Yasuda Y; Taniguchi T; Kozuka S; Matano K; Maeyama J; Morokuma K; Ohkuma K; Goto N; Tochikubo K
    Vaccine; 2003 Mar; 21(11-12):1165-73. PubMed ID: 12559794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Storage at -3 degrees C for 24 h alters the immunogenicity of pertussis vaccines.
    Boros CA; Hanlon M; Gold MS; Roberton DM
    Vaccine; 2001 May; 19(25-26):3537-42. PubMed ID: 11348721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.